Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset.

ABSTRACT:

Introduction

We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib.

Methods

This is a non-interventional, cross-sectional, questionnaire based telephonic study which included consecutive AIRD patients on tofacitinib co-treatment. Data related to the AIRD subset, disease modifying anti rheumatic drugs(DMARDs) including glucocorticoids and comorbidities, was collected from 7 rheumatology centers across Karnataka during the second wave of COVID-19 pandemic. The information about COVID-19 occurrence and COVID-19 vaccination was recorded.

Results

During the study period (Jun-July 2021), 335 AIRD patients (80.6% female) on treatment with tofacitinib we

SUBMITTER: Chebbi P 

PROVIDER: S-EPMC10369741 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature